glp 1 and aromatase inhibitors Frontiers GLP-1 receptor agonists and next-generation

Results The search strategy identified 833 hits, of which 42 studies were included in the final review

Find which approach fits your specific goals.

Accompanied by predic

Salas-Whalen reveals that body composition testing, not just the number on your scale, is key to knowing whether GLP-1 weight-loss medications are right for you.

Tirzepatide (Zepbound/Mounjaro): A dual GLP-1/GIP receptor agonist undergoing evaluation for MASH after demonstrating significant liver fat reduction in studies.Retatrutide: A "triple agonist" targeting GLP-1, GIP, and glucagon (GCGR) receptors, which has shown "unprecedented" efficacy in weight loss and is being evaluated for metabolic diseases including MASH